$4.73
20.66%
Nasdaq, Jul 07, 10:19 pm CET
ISIN
US83548R1059
Symbol
SONN
Sector
Industry

Sonnet BioTherapeutics Holdings Inc Target price 2025 - Analyst rating & recommendation

Sonnet BioTherapeutics Holdings Inc Classifications & Recommendation:

Buy
86%
Hold
14%

Sonnet BioTherapeutics Holdings Inc Price Target

Target Price $20.40
Price $3.92
Potential
Number of Estimates 3
3 Analysts have issued a price target Sonnet BioTherapeutics Holdings Inc 2026 . The average Sonnet BioTherapeutics Holdings Inc target price is $20.40. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 7 analysts: 6 Analysts recommend Sonnet BioTherapeutics Holdings Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Sonnet BioTherapeutics Holdings Inc stock has an average upside potential 2026 of . Most analysts recommend the Sonnet BioTherapeutics Holdings Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Sep '24 2025
Estimates
Revenue Million $ 0.02 1.02
86.67% 5,000.00%
EBITDA Margin -58,850.00% -4,530.00%
371.55% 92.30%
Net Margin -37,200.00% -1,079.52%
196.34% 97.10%

3 Analysts have issued a sales forecast Sonnet BioTherapeutics Holdings Inc 2025 . The average Sonnet BioTherapeutics Holdings Inc sales estimate is

$1.0m
Unlock
. This is
2.00% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$1.1m 5.00%
Unlock
, the lowest is
$980k 2.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $20.0k 86.67%
2025
$1.0m 5,000.00%
Unlock

3 Analysts have issued an Sonnet BioTherapeutics Holdings Inc EBITDA forecast 2025. The average Sonnet BioTherapeutics Holdings Inc EBITDA estimate is

$-46.2m
Unlock
. This is
238.26% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-47.6m 248.21%
Unlock
, the lowest is
$-44.4m 224.99%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-11.8m 37.13%
2025
$-46.2m 292.57%
Unlock

EBITDA Margin

2024 -58,850.00% 371.55%
2025
-4,530.00% 92.30%
Unlock

3 Sonnet BioTherapeutics Holdings Inc Analysts have issued a net profit forecast 2025. The average Sonnet BioTherapeutics Holdings Inc net profit estimate is

$-11.0m
Unlock
. This is
17.16% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-10.6m 20.39%
Unlock
, the lowest is
$-11.3m 14.75%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-7.4m 60.49%
2025
$-11.0m 47.98%
Unlock

Net Margin

2024 -37,200.00% 196.34%
2025
-1,079.52% 97.10%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Sep '24 2025
Estimates
Earnings Per Share $ -11.35 -3.53
92.18% 68.90%
P/E negative
EV/Sales 10.15

3 Analysts have issued a Sonnet BioTherapeutics Holdings Inc forecast for earnings per share. The average Sonnet BioTherapeutics Holdings Inc EPS is

$-3.53
Unlock
. This is
4.44% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-3.63 7.40%
Unlock
, the lowest is
$-3.39 0.30%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-11.35 92.18%
2025
$-3.53 68.90%
Unlock

P/E ratio

Current -1.16 113.39%
2025
-1.11 4.29%
Unlock

Based on analysts' sales estimates for 2025, the Sonnet BioTherapeutics Holdings Inc stock is valued at an EV/Sales of

10.15
Unlock
and an P/S ratio of
12.17
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 10.35 218.69%
2025
10.15 1.96%
Unlock

P/S ratio

Current 12.41 57.47%
2025
12.17 1.96%
Unlock

Current Sonnet BioTherapeutics Holdings Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Chardan Capital
Locked
Locked
Locked Apr 07 2025
Chardan Capital
Locked
Locked
Locked Mar 28 2025
Chardan Capital
Locked
Locked
Locked Dec 20 2024
Chardan Capital
Locked
Locked
Locked Aug 23 2024
Analyst Rating Date
Locked
Chardan Capital:
Locked
Locked
Apr 07 2025
Locked
Chardan Capital:
Locked
Locked
Mar 28 2025
Locked
Chardan Capital:
Locked
Locked
Dec 20 2024
Locked
Chardan Capital:
Locked
Locked
Aug 23 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today